Literature DB >> 18409175

On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives.

Roberto Pellicciari1, Emidio Camaioni, Gabriele Costantino, Laura Formentini, Paola Sabbatini, Francesco Venturoni, Gökçen Eren, Daniele Bellocchi, Alberto Chiarugi, Flavio Moroni.   

Abstract

PARP-1 and PARP-2 are members of the family of poly(ADP-ribose)polymerases, which are involved in the maintenance of genomic integrity under conditions of genotoxic stimuli. The different roles of the two isoforms under pathophysiological conditions have not yet been fully clarified, and this is partially due to the lack of selective inhibitors. We report herein the synthesis and preliminary pharmacological evaluation of a large series of isoquinolinone derivatives as PARP-1/PARP-2 inhibitors. Among them, we identified the 5-benzoyloxyisoquinolin-1(2 H)-one derivative as the most selective PARP-2 inhibitor reported so far, with a PARP-2/PARP-1 selectivity index greater than 60.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18409175     DOI: 10.1002/cmdc.200800010

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  15 in total

Review 1.  Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.

Authors:  Amos A Fatokun; Valina L Dawson; Ted M Dawson
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

2.  Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease.

Authors:  Hanna Shevalye; Yury Maksimchyk; Pierre Watcho; Irina G Obrosova
Journal:  Biochim Biophys Acta       Date:  2010-07-16

3.  Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.

Authors:  Bin Gui; Fu Gui; Tomoaki Takai; Chao Feng; Xiao Bai; Ladan Fazli; Xuesen Dong; Shuai Liu; Xiaofeng Zhang; Wei Zhang; Adam S Kibel; Li Jia
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-02       Impact factor: 11.205

4.  PARP inhibition delays progression of mitochondrial encephalopathy in mice.

Authors:  Roberta Felici; Leonardo Cavone; Andrea Lapucci; Daniele Guasti; Daniele Bani; Alberto Chiarugi
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

Review 5.  The potential of PARP inhibitors in neuro-oncology.

Authors:  Ross Carruthers; Anthony J Chalmers
Journal:  CNS Oncol       Date:  2012-09

6.  Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage.

Authors:  F Moroni; L Formentini; E Gerace; E Camaioni; D E Pellegrini-Giampietro; A Chiarugi; R Pellicciari
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

Review 7.  Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation.

Authors:  Valerie C Besson
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

8.  Solution-phase synthesis of a diverse isocoumarin library.

Authors:  Sujata Roy; Sudipta Roy; Benjamin Neuenswander; David Hill; Richard C Larock
Journal:  J Comb Chem       Date:  2009 Nov-Dec

Review 9.  Poly(ADP-ribose) polymerase-2: emerging transcriptional roles of a DNA-repair protein.

Authors:  Magdolna Szántó; Attila Brunyánszki; Borbála Kiss; Lilla Nagy; Pál Gergely; László Virág; Péter Bai
Journal:  Cell Mol Life Sci       Date:  2012-05-13       Impact factor: 9.261

Review 10.  Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.

Authors:  Yuan Yuan; Yu-Min Liao; Chung-Tsen Hsueh; Hamid R Mirshahidi
Journal:  J Hematol Oncol       Date:  2011-04-20       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.